Press Releases

  • All
  • Press Release 2022
  • Press Release 2023
  • Press Releases 2009
  • Press Releases 2010
  • Press Releases 2011
  • Press Releases 2012
  • Press Releases 2014
  • Press Releases 2017
  • Press Releases 2018
  • Press Releases 2019
  • Press Releases 2020
  • Press Releases 2021

Peania, 21 September 2023– Lavipharm (LAVI) reports a significant increase in consolidated sales and EBITDA during the First Half of 2023. The impressive results exceed sales forecasts, as disclosed in the prospectus of the recent share capital increase, for a second consecutive year. Specifically, consolidated Sales,...

Peania, 19 September 2023 - Lavipharm joins voices with MDA Hellas, that organizes a unique concert featuring the leading singer-songwriter Nikos Portokaloglou and the renowned singer Rena Morfi. The concert will take place tomorrow, 20 September (21.00) at the Veakio Municipal Theatre of Piraeus. The concert...

Peania, 7 September 2023 – Lavipharm, a long-time supporter of MDA Hellas, the Association for the Care of People with Neuromuscular Diseases, is participating as a sponsor in the online event that will take place today, September 7, 2023, at 17:00, organized in the framework...

Peania, 6 July 2023 – Lavipharm’s (LAVI) Annual Shareholders Meeting was held today at the corporate headquarters in Peania. The meeting was completed with the necessary quorum, as 33 shareholders participated representing a percentage 70.78%. The General Assembly began its proceedings with the welcome speech of...

Vicky D. Kefalas joins Lavipharm’s Board of Directors Establishment of a long-term incentive plan Peania, 26 May 2023 – Lavipharm’s Extraordinary Shareholders Meeting, held at today at the corporate headquarters, decided in favor of the election of a new member of the Board of Directors and the...

Peania, 1 February 2023 – Lavipharm continues to expand its product portfolio in the Greek market by adding one more pharmaceutical product in the category of Urology. It is a fixed combination of dutasteride and tamsulosin addressing the symptoms of benign prostatic hyperplasia (BPH). Lavipharm’s...

Peania, 27 January 2023 – Lavipharm received an award from the National and Kapodistrian University of Athens (NKUA) in recognition of its many years of activity in the research, development and production of pharmaceutical products and its longstanding collaboration with the Department of Pharmacy of...

A new page in its presence on the stock exchange Peania, 22 December 2022 – As of Friday, 23 December 2022, the shares of Lavipharm S.A. will be traded again on the Main Market of the Athens Stock Exchange. Following the completion of the share capital increase,...

Peania, 22 December 2022 – As of Friday, 23 December 2022, the shares of Lavipharm S.A. will be traded again on the Main Market of the Athens Stock Exchange. Following the completion of the share capital increase, the Listings and Market Operation Committee of the Athens...

Παιανία, 22 Δεκεμβρίου 2022 - Η «Ανώνυμη Εμπορική και Βιομηχανική Εταιρία Φαρμακευτικών, Χημικών και Καλλυντικών Προϊόντων LAVIPHARM A.E.» (εφεξής «Εταιρεία») ανακοινώνει ότι από την 23.12.2022 θα αρχίσει η διαπραγμάτευση στο Χρηματιστήριο Αθηνών των 150.841.472 νέων κοινών ονομαστικών μετοχών της Εταιρείας, ονομαστικής αξίας 0,30 ευρώ η...